CLAIMS

1. A pharmaceutical formulation comprising:

(a) an anti-c-met antibody, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6) and wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex;

(b) a histidine buffer at pH 5.0-5.4;

(c) a saccharide; and

(d) a polysorbate, wherein the polysorbate is present at greater than 0.02% w/v.

2. The pharmaceutical formulation of claim 1, wherein the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDT RFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTV SS (SEQ ID NO:19) and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).

3. The pharmaceutical formulation of claim 2, wherein the first and second Fc polypeptides form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.

4. The pharmaceutical formulation of any one of claim 1-3, wherein the anti-c-met antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:19, a CH1 sequence, and a first Fc polypeptide and (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:20 and CL1 sequence.

5. The pharmaceutical formulation of claim 4, wherein the anti-c-met antibody further comprises (c) a third polypeptide comprising a second Fc polypeptide.

6. The pharmaceutical formulation of any one of claims 1-5, wherein the first Fc polypeptide comprises the Fc sequence depicted in Figure 2 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in Figure 3 (SEQ ID NO: 18).

7. The pharmaceutical formulation of any one of claims 1-6, wherein the anti-c-met antibody

is onartuzumab.

8. The pharmaceutical formulation of any one of claims 1-7, wherein the anti-c-met antibody binds the same epitope as onartuzumab.

9. The pharmaceutical formulation of any one of claims 1-8, wherein the anti-c-met antibody is present at a concentration between about 10 mg/mL and about 100 mg/mL (*e.g.* about 15 mg/mL and about 75 mg/mL).

10. The pharmaceutical formulation of claim 9, wherein the anti-c-met antibody is present at a concentration of about 60 mg/mL.

11. The pharmaceutical formulation of any one of claims 1-10, wherein the saccharide is present at a concentration of about 75 mM to about 200 mM (*e.g.*, about 100 mM to about 150 mM).

12. The pharmaceutical formulation of claim 11, wherein the saccharide is present at a concentration of about 120 mM.

13. The pharmaceutical formulation of any one of claims 1-12, wherein the saccharide is a disaccharide.

14. The pharmaceutical formulation of claim 13, wherein the disaccharide is trehalose.

15. The pharmaceutical formulation of claim 13, wherein the disaccharide is sucrose.

16. The pharmaceutical formulation of any one of claims 1-15, wherein the histidine buffer is at a concentration of about 1 mM to about 50 mM (*e.g.* about 1 mM to about 25 mM).

17. The pharmaceutical formulation of claim 16, wherein the histidine buffer is at a concentration of about 10 mM.

18. The pharmaceutical formulation of any one of claims 1-17, wherein the histidine buffer is histidine acetate.

19. The pharmaceutical formulation of any one of claims 1-18, wherein the polysorbate is present at a concentration greater than 0.02% and less than about 0.1%.

20. The pharmaceutical formulation of claim 19, wherein the polysorbate is present at a concentration of about 0.04%.

21. The pharmaceutical formulation of any one of claims 1-20, wherein the polysorbate is polysorbate 20.

22. The pharmaceutical formulation of any one of claims 1-21, wherein the formulation is diluted with a diluent (*e.g.*, 0.9% NaCl).

23. The pharmaceutical formulation of claim 22, wherein the anti-c-met antibody is present at a concentration of about 1 mg/mL.

24. A method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation of any one

of claims 1-23.

25. A method of modulating a disease associated with dysregulation of the HGF/c-met signaling axis, said method comprising administering to a subject an effective amount of the pharmaceutical formulation of any one of claims 1-23.

26. A method of treating a subject having a proliferative disorder, said method comprising administering to the subject an effective amount of the pharmaceutical formulation of any one of claims 1-23.

27. The method of claim 26, wherein the proliferative disorder is cancer.

28. The method of claim 27, wherein the cancer is lung cancer (*e.g.*, non-small cell lung cancer (NSCLC)), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.

29. The method of any one of claims 24-28, further comprising a second therapeutic agent.

30. A method of making a pharmaceutical formulation of any one of claims 1-23.

31. An article of manufacture comprising a container with the pharmaceutical formulation of any one of claims 1-23 contained therein.

32. A method of making the article of manufacture of claim 31.

CLAIMS

1. A pharmaceutical formulation comprising:

(a) an anti-c-met antibody, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6) and wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex;

(b) a histidine buffer at pH 5.0-5.4;

(c) a saccharide; and

(d) a polysorbate, wherein the polysorbate is present at greater than 0.02% w/v.

2. The pharmaceutical formulation of claim 1, wherein the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDT RFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTV SS (SEQ ID NO:19) and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).

3. The pharmaceutical formulation of claim 2, wherein the first and second Fc polypeptides form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.

4. The pharmaceutical formulation of any one of claim 1-3, wherein the anti-c-met antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:19, a CH1 sequence, and a first Fc polypeptide and (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:20 and CL1 sequence.

5. The pharmaceutical formulation of claim 4, wherein the anti-c-met antibody further comprises (c) a third polypeptide comprising a second Fc polypeptide.

6. The pharmaceutical formulation of any one of claims 1-5, wherein the first Fc polypeptide comprises the Fc sequence depicted in Figure 2 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in Figure 3 (SEQ ID NO: 18).

7. The pharmaceutical formulation of any one of claims 1-6, wherein the anti-c-met antibody

is onartuzumab.

8. The pharmaceutical formulation of any one of claims 1-7, wherein the anti-c-met antibody binds the same epitope as onartuzumab.

9. The pharmaceutical formulation of any one of claims 1-8, wherein the anti-c-met antibody is present at a concentration between about 10 mg/mL and about 100 mg/mL (*e.g.* about 15 mg/mL and about 75 mg/mL).

10. The pharmaceutical formulation of claim 9, wherein the anti-c-met antibody is present at a concentration of about 60 mg/mL.

11. The pharmaceutical formulation of any one of claims 1-10, wherein the saccharide is present at a concentration of about 75 mM to about 200 mM (*e.g.*, about 100 mM to about 150 mM).

12. The pharmaceutical formulation of claim 11, wherein the saccharide is present at a concentration of about 120 mM.

13. The pharmaceutical formulation of any one of claims 1-12, wherein the saccharide is a disaccharide.

14. The pharmaceutical formulation of claim 13, wherein the disaccharide is trehalose.

15. The pharmaceutical formulation of claim 13, wherein the disaccharide is sucrose.

16. The pharmaceutical formulation of any one of claims 1-15, wherein the histidine buffer is at a concentration of about 1 mM to about 50 mM (*e.g.* about 1 mM to about 25 mM).

17. The pharmaceutical formulation of claim 16, wherein the histidine buffer is at a concentration of about 10 mM.

18. The pharmaceutical formulation of any one of claims 1-17, wherein the histidine buffer is histidine acetate.

19. The pharmaceutical formulation of any one of claims 1-18, wherein the polysorbate is present at a concentration greater than 0.02% and less than about 0.1%.

20. The pharmaceutical formulation of claim 19, wherein the polysorbate is present at a concentration of about 0.04%.

21. The pharmaceutical formulation of any one of claims 1-20, wherein the polysorbate is polysorbate 20.

22. The pharmaceutical formulation of any one of claims 1-21, wherein the formulation is diluted with a diluent (*e.g.*, 0.9% NaCl).

23. The pharmaceutical formulation of claim 22, wherein the anti-c-met antibody is present at a concentration of about 1 mg/mL.

24. The use of the pharmaceutical formulation of any one of claims 1-23 in the manufacture of a medicament for inhibiting c-met activated cell proliferation.

25. The use of the pharmaceutical formulation of any one of claims 1-23 in the manufacture of a medicament for modulating a disease associated with dysregulation of the HGF/c-met signaling axis.

26. The use of the pharmaceutical formulation of any one of claims 1-23 in the manufacture of a medicament for treating a subject having a proliferative disorder.

27. The use of claim 26, wherein the proliferative disorder is cancer.

28. The use of claim 27, wherein the cancer is lung cancer (*e.g.*, non-small cell lung cancer (NSCLC)), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.

29. The use of any one of claims 24-28, wherein the medicament comprises a second therapeutic agent.

30. A method of making a pharmaceutical formulation of any one of claims 1-23.

31. An article of manufacture comprising a container with the pharmaceutical formulation of any one of claims 1-23 contained therein.

32. A method of making the article of manufacture of claim 31.

33. An *in vitro* method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation of any one of claims 1-23.

34. The method of claim 33, further comprising a second therapeutic agent.